Brain and pituitary fibroblast growth factors (FGF) have been purified to apparent homogeneity from crude tissue extracts by a three-step procedure, including salt precipitation, ion-exchange chromatography, and heparin-Sepharose affinity chromatography. Brain and pituitary FGF have similar amino acid compositions and are indistinguishable with respect to molecular weight (16,000 by polyacrylamide gel electrophoresis), retention behavior in reversed-phase high-performance liquid chromatography, and recognition by antibodies directed against the amino-terminal sequence of pituitary FGF. Brain FGF preparations purified by heparinSepharose contain, in addition to the major FGF molecular species, at least two additional forms of the growth factor, which appear to be very similar by all the above criteria, except for retention in high-performance liquid chromatography.
Previous studies have shown that potent mitogens for mesoderm-derived cells, particularly for vascular endothelial cells, are present in both brain and pituitary tissue (1, 2) . These factors, first detected on the basis of their ability to stimulate the proliferation of fibroblasts, have been named pituitary and brain fibroblast growth factors (1) . They are basic mitogens (pl, 9.6) composed of single polypeptide chains with molecular weights of 14,000-16,000 (3, 4) . We have recently isolated pituitary fibroblast growth factor (FGF) and determined its amino-terminal sequence to be Pro-Ala-Leu-Pro-Glu-Asp-Gly-Gly-Ser-Gly-Ala-Phe-ProPro-Gly (5). Brain FGF had previously been characterized as two fragments of myelin basic protein (MBP) (4, 6) , an identification subsequently disputed (7, 8) .
We have developed a new procedure for the isolation of FGF using heparin-Sepharose affinity chromatography (HSAC), as described by Shing et al. (9) , for the purification of a chondrosarcoma-derived basic growth factor. We report here the purification to apparent homogeneity of basic brain and pituitary FGFs, which appear to be identical. This finding resolves the previous controversy concerning the chemical nature of brain FGF.
EXPERIMENTAL PROCEDURES Materials. Frozen brain and pituitary tissues were obtained from J. R. Scientific (Woodland, CA), kept in a Revco freezer (-800C) , and used within a period of 2 weeks. All reagents were of analytical grade. Carboxymethyl-Sephadex C-50 and heparin-Sepharose were from Pharmacia. The Vydac C4 reversed-phase HPLC column was from Separations Group (Hesperia, CA). Crystalline bovine serum albumin was from Schwarz/Mann. The Bio-Rad protein assay kit, low molecular weight standards for NaDodSO4/polyacrylamide gel electrophoresis, and the silver nitrate stain kit were from Bio-Rad. Dulbecco's modified Eagle's medium (DME medium) H-16 was from GIBCO. Calf serum was from Hyclone, Sterile Systems (Logan, UT).
Isolation of Brain and Pituitary FGF. Bovine brains (4 kg) or pituitaries (1.8 kg) were extracted with 0.15 M ammonium sulfate (pH 4.5) as described (1, 3, 4) . Partially purified FGF was prepared by ammonium sulfate precipitation and batch adsorption/elution, using carboxymethyl Sephadex C-50, as described (3, 4) . FGF-containing fractions eluting from the ion-exchange column with 0.6 M NaCl/0.1 M sodium phosphate, pH 6.0, were pumped (35 ml/hr) through a heparinSepharose column (1.6 x 5 cm; bed vol, 10 ml) that had been equilibrated at room temperature with 10 mM Tris HCl, pH 7.0/0.6 M NaCI. The column was washed (flow rate 35 ml/ hr) with 10 mM Tris HCl, pH 7.0/0.6 M NaCl, and then with 10 mM Tris HCl, pH 7.0/1.1 M NaCl, until the absorbance of the eluate at 280 nm became negligible. Mitogenic activity was then eluted with a linear 2-hr salt gradient of 1.1 M to 2 M NaCl in 10 mM Tris HCl (pH 7.0) at 35 ml/hr. Fractions with biological activity were pooled and kept frozen at -80'C. Unless otherwise stated, total protein was determined by the dye fixation assay (10), using bovine serum albumin as a standard, and/or by amino acid analysis (see below). Aliquots of HSAC-purified FGF were analyzed by reserved-phase HPLC on a Vydac C4 column [25 x 0.46 cm; particle size, S ,tm; pore size, 300 A; using a gradient of acetonitrile in 0.1% (vol/vol) trifluoroacetic acid]. Further details are contained in the figure legends.
Amino Acid Analysis. Amino acid analysis was performed on a Liquimat III analyzer (Kontron, Zurich, Switzerland) equipped with an o-phthalaldehyde fluorescence detection system and a proline conversion accessory according to previously described micromethodology (11) . NaDodSO4/PAGE. Aliquots (0.5 ,ug of protein) from the bioactive HSAC fractions were added to a sample buffer composed of 15% (vol/vol) glycerol/0.1 M dithiothreitol/2% (wt/vol) NaDodSO4/75 mM Tris'HCl, pH 6.8/2 mM phenylmethylsulfonyl fluoride/2 mM EDTA/1 mM N-ethylmaleimide/1 mM iodoacetic acid. Samples were boiled for 3 min and then applied to an exponential gradient (10%-18%) polyacrylamide slab gel with a 3% stacking gel (12, 13) . Electro- phoresis' was for 4 hr at 20 mA. Gels were stained using the Bio-Rad silver nitrate stain kit as described by the manufacturer (14) .
Bioassay. The mitogenic activity of column fractions was determined using bovine vascular endothelial cells derived from adult aortic arch as described (7, 15 were seeded at an initial density of 2 x 104 cells per 35-mm dish containing 2 ml of DME medium H-16 supplemented with 10% calf serum and antibiotics (7, 15) . Six hours later, a set of triplicate plates was trypsinized and cells were counted to determine the plating efficiency. Ten-microliter aliquots of the appropriate dilution of each fraction (with DME medium/0.5% bovine serum albumin) were then added to the dishes every other day. After 4 days in culture, triplicate plates were trypsinized, and final cell densities were determined by counting cells in a Coulter counter.
RIA. Amino-terminally directed antibodies against pituitary FGF were obtained by immunizing 3-month-old male (1984) and female New Zealand White rabbits against the bovine serum albumin-conjugated synthetic decapeptide Pro-AlaLeu-Pro-Glu-Asp-Gly-Gly-Ser-Tyr [Tyr10-FGF(1-9)I, which represents the amino-terminal sequence of pituitary FGF (5) . These antibodies recognize both synthetic antigen and native pituitary FGF on an equimolar basis and are capable of inhibiting the FGF-induced proliferation of vascular endothelial cells in vitro (5) . An RIA was established using the radioiodinated antigen as a tracer and antiserum (716 B4 and B8) at a final dilution of 1:5000 (5).
RESULTS
Isolation of Brain and Pituitary FGF. The heparin-Sepharose affinity chromatography profile of partially purified brain FGF is shown in Fig. 1 . Most of the protein (>99%) was not retained by the column (Fig. lA) , and the unadsorbed material had little biological activity (<0.3% that of the input) (Fig. 1B) . Elution of the column with 1.1 M NaCl resulted in the elution of another protein fraction with little chromatographed on a heparin-Sepharose column. Fractions of 10 ml and 3 ml were collected during sample loading and column washing; fractions of 1.4 ml were collected during gradient elution. Protein concentration in fractions 5-14 was determined by weighing a 2-ml aliquot after dialysis and lyophilization. For bioassay, aliquots of the pooled fractions 5-14, 28-30, and 31-33 were diluted with DME medium/0.5% bovine serum albumin, and 10-pil aliquots containing 2 ,.g, 16 ng, and 4 ng, respectively, were added to low density ABAE cell cultures. Bioassay results for these pooled fractions are shown in histogram form. Aliquots of fractions 50-67 of the NaCl gradient were diluted 1:500 in DME medium/0.5% bovine serum albumin, and 10-jl aliquots were added to low-density ABAE cell The pituitary FGF preparation (0.6 M NaCl carboxymethyl Sephadex eluate, 124 ml, 7 mg/ml) was chromatographed on a heparin-Sepharose column, as described in Fig. 1A . Protein concentrations in fractions 6-15, 33-34, and 54-64 were determined as described in Fig. 1A . Ten microliters of the pooled fractions 6-15 and 33-34, containing 2 and 10 ng of protein, respectively, and fractions 54-64 of the NaCl gradient were assayed as outlined in tOne unit of activity is defined as the quantity of FGF required to give half-maximal stimulation of cell proliferation in the assay system described.
biological activity (Fig. 1B) . Gradient elution of the column yielded a single protein peak eluting at 1.5-1.6 M NaCl (fractions 50-67). This fraction contained most of the biological activity (83%; Table 1 ), with maximal stimulation of cell proliferation occurring at 0.4 ng/ml and half-maximal response at 40 pg/ml (Fig. iB) . The yield of brain FGF in five different preparations ranged from 30 to 55 /ig per kg of brain.
A similar profile was observed when partially purified pituitary FGF was chromatographed on heparin-Sepharose (Fig. 2) . The material in fractions 54-64 stimulated adult bovine aortic endothelial cell (ABAE cell) proliferation maximally at a concentration of 0.4 ng/ml, while half-maximal response occurred with 50 pg/ml. Recovery of biological activity was 80% that of the input ( Table 1 16 ,000 (Fig. 3) . The migratory behavior of USAC-purified brain and pituitary FGF was identical to that of homogeneous pituitary FGF, which we had isolated using different procedures (5).
Reversed-phase HPLC analyses of HSAC-purified brain and pituitary FOF are shown in Fig. 4 . Pituitary FGF is highly pure, as judged by the presence of only minor impurities eluting before and after the biologically active UV absorbing peak (Fig. 4A) . The impurities amount to <10% of the material eluting in the main peak. In contrast, the elution profile of HSAC-purified brain FGF shows four distinct peaks (Fig.  4B) , the largest (fraction 19) having a retention time identical to that of pituitary FGF. The three additional peaks (fractions 22, 25, and 30) do not represent unrelated impurities, because they possess biological activity. Furthermore, pituitary FGF and all forms of brain FGF are immunoreactive when assayed in an RIA using amino-terminally directed antibodies against pituitary FGF (Fig. 4 A and B) . The amino acid compositions of HSAC-purified brain and pituitary FGFs are strikingly similar- (Table 2 ) and are very close to that of pituitary FGF isolated by different procedures (5). This constitutes additional evidence for the purity of heparin-purified FGF from both pituitary and brain. Interestingly, the amino acid compositions of the three forms of brain FGF as seen by HPLC are all similar (data not shown), suggesting that the various forms of brain FGF may be structurally related.
DISCUSSION
A three-step purification procedure has been developed for the isolation of brain and pituitary FGF. The method includes ammonium sulfate precipitation, adsorption to carboxymethyl Sephadex, and HSAC, and it yields substantial amounts of highly purified (>90%) brain or pituitary FGF in <48 hr. The heparin-Sepharose step alone is responsible for 2400-and 5300-fold purification of pituitary and brain FGF, respectively, thus constituting an extremely powerful technique. Brain and pituitary FGFs purified by HSAC possess the full intrinsic activity and the same potency as fast-protein liquid chromatography (FPLC)-purified pituitary FGF (5). Exposure of HSAC-purified FGF to acidic conditions of reversed-phase HPLC (Fig. 4 ) results in drastic reduction (95%) of biological potency. This inactivation is similar to that found previously for pituitary FGF purified by other procedures (5) .
Our combined data (molecular weight, HPLC retention time, amino acid composition, immunoactivity, and bioactivity) suggest that pituitary FGF and the major form of brain FGF are structurally similar, possibly even identical. This conclusion is further supported by our preliminary finding (data not shown) that HSAC-purified brain and pituitary FGFs are also indistinguishable with respect to their immunoreactivity with murine 1gM monoclonal antibodies raised against homogeneous pituitary FGF prepared by FPLC as described (5) .
Brain FGF consists of multiple molecular forms, which appear to be structurally related based on their close similarities with respect to immuno-and bioreactivities and on their amino acid compositions and molecular weights. Since all 92. X (Fig. 1A) was diluted with 930 A.l of 0.2 M acetic acid and 1 ml was injected into a C4 column equilibrated in 0.1% (vol/vol) trifluoroacetic acid. Protein was eluted with a linear 90-min acetonitrile gradient in 0.1% trifluoroacetic acid [26%-36% (vol/vol) acetonitrile]. Flow rate was 0.6 ml/min, and fractions of 1.8 ml were collected. Aliquots of each fraction were bioassayed as described in Fig. 1 . Twenty-microliter aliquots were subjected to RIA. Absorbance peaks corresponding to fractions 2-3 and fractions 34-35 did not contain significant amounts of protein (by amino acid analysis). (B) Brain FGF: 1 ml (22 pug of protein) of the pooled fractions 55-62 ( Fig. 2A) was chromatographed as described for A. Bioassay was carried out as described above, except that aliquots of each fraction were diluted 1:10 with DME medium/0.5% bovine serum albumin for assay. RIA was carried out as described above. Material in fraction 30, corresponding to the last UV-absorbing peak, was immunoreactive when assayed at a higher dose. Absorbance peaks corresponding to fractions 2-4 and 34-35 did not contain protein (by amino acid analysis).
forms are recognized by specific antisera raised against a synthetic replicate of the amino-terminal sequence of pituitary FGF (5) , it is likely that all forms of brain FGF share the same amino-terminal sequence already determined for pituitary FGF-Pro-Ala-Leu-Pro-Glu-Asp-Gly-Gly-Ser-or a sequence very similar. (8, 19, 20) , we find that >99% of the bioactivity subjected to heparin chromatography is strongly bound by heparin-Sepharose. The high recovery of FGF (80%-83%) in the 1.5-1.6 M NaCl fractions, and the presence of only small amounts of bioactivity in side fractions from the ammonium sulfate and carboxymethyl Sephadex steps (3, 4, 7) , indicate that FGF, as characterized in this report, is the major form of mitogen present in acidic extracts of brain and pituitary tissue. This is in contrast with earlier reports (8, 20) claiming that significant amounts of acidic FGF can be present in partially purified preparations of brain or pituitary extracted at pH 4.5. It is also in contrast with a recent report (21) describing the purification to homogeneity of an anionic form of FGF from acidic (pH 4.5) brain extracts. Apparently multiple forms of FGF are present in brain that are biologically, but not necessarily structurally, related. The isolation of basic or acidic FGF as the major mitogenic form may depend on minor differences in the isolation protocols or assays used.
The present study establishes the virtual identity of basic brain and pituitary FGF. Since pituitary FGF has been partially characterized structurally (5) and has been shown to be 0 4o Proc..Natl. Acad Sci. USA 81 (1984) unlike any MBP fragment,. the previous identification of brain FGF as degradation products of MBP (6) must be considered erroneous. It is likely that, as suggested by others (8) , brain FGF copurified with MBP fragments when brain extracts were processed through the purification scheme described (4) . Although both brain and pituitary FGF are different from all other growth factors identified to date, they share common properties with a chondrosarcoma growth factor (CGF), which is mitogenic for capillary endothelial cells (9) . FGF and CGF are basic growth factors (pl, 9.6) that have similar molecular weights (16, (0) (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) ,000 for brain and pituitary FGF, and 17,000-18,000 for CGF) and are mitogenic for vascular endothelial cells. They also share the property of being angiogenic in vivo (9, 22) . The question of whether FGF and CGF are related molecules can only be answered when their complete structural characterization has been accomplished.
Note Added in Proof. Recent studies using bovine adrenal cortex capillary endothelial cells have shown that those cells are even more dependent on FGF in order to proliferate and preserve their phenotype than ABAE cells (unpublished observations). The amino-terminal sequence of the various forms of brain FGF has been determined and is identical in all cases.
